Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 11-20 of 91 for lymphoma

  • Results filtered:
  • Study status: Open/Status Unknown
Edit search filters
  1. A Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone Lymphoma

    Rochester, MN

  2. A Study to Evaluate the Safety and Effectiveness of Autologous Cells Expressing Anti-CD20 and Anti-CD19 in Relapsed/Refractory Diffuse Large B Cell Lymphoma Patients

    Scottsdale/Phoenix, AZ, Rochester, MN

  3. Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma

    Scottsdale/Phoenix, AZ, Rochester, MN

  4. A Study to Evaluate the Safety and Effectiveness of ALLO-501A CAR T Cell Therapy in Adults with Relapsed/ Refractory Large B Cell Lymphoma

    Scottsdale/Phoenix, AZ

  5. Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)

    Rochester, MN

  6. LS1681: A Study of AR160 in Treating Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

    Rochester, MN

  7. A Study to Evaluate LOXO-305 Vs. Approved BTK Inhibitor Approved Drugs to Treat Patients with Mantle Cell Lymphoma

    Jacksonville, FL, Rochester, MN

  8. A Study to Evaluate Feasibility of In Vivo Sensitivity Screen Using Direct Tumor Microinjection and FDG-PET in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer

    Rochester, MN

  9. An Open-label Study to Assess the Anti-Tumor Activity and Safety of REGN1979, an Anti-CD20 X Anti-CD3 Bispecific Antibody, in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

    Rochester, MN

  10. Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)

    Rochester, MN, Rochester, MN

.

Mayo Clinic Footer